Pharma’s Response to the Coronavirus
America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a novel strain of coronavirus that originated in Wuhan, China. In addition to applying scientific expertise to find ways to diagnose, treat and prevent infection from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S. Chinese and global health authorities to combat this global public health emergency.
PQMD members responding include:
Abbvie: In late January, the Chinese health authorities identified Aluvia (lopinavir/ritonavir) as a potential treatment for the coronavirus and requested supply. AbbVie donated approximately $2 million (USD) of Aluvia as an experimental option to help address the crisis.
Boehringer Ingelheim (BI): BI has made a number of donations totaling more than $1 million (USD) to China Red Cross Foundation to purchase medical protective materials for hospitals. The headquarters of BI also purchased 100,000 protective masks from Germany, which are donated to medical staff. BI has also donated medicines to help treat patients with new pneumonia in Wuhan.
GlaxoSmithKline (GSK): GSK and the Coalition for Epidemic Preparedness Innovations, formed a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV virus. In this new move, GSK will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine.
Johnson & Johnson (J&J): J&J is seeking to further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.
Sanofi: Sanofir Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-10 vaccine. Sanofi is collaborating with BARDA, expanding the company’s long-standing partnership with the Authority.
To read more, visit this website.